Skip to main content
Erschienen in: Drugs & Aging 3/2011

01.03.2011 | Original Research Article

Effects of Anticholinergic Drugs on Verbal Episodic Memory Function in the Elderly

A Retrospective, Cross-Sectional Study

verfasst von: Dr Marie-Pierre Fortin, Isabelle Rouch, Virginie Dauphinot, Claire Gédéon, Stella Genthon, Marc Bonnefoy, Pierre Krolak-Salmon

Erschienen in: Drugs & Aging | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

An increasing number of medications that are frequently prescribed to elderly patients have been identified as having weak but definite anticholinergic properties. Few epidemiological studies have evaluated the impact of these drugs on verbal episodic memory using sensitive and specific neuropsychological testing in an elderly population presenting with cognitive impairment.

Objectives

The aim of this study was to assess the effect of drugs with anticholinergic properties on verbal episodic memory function in elderly patients presenting for memory evaluation.

Study Design

We performed a retrospective, cross-sectional study that included 134 consecutive elderly outpatients who attended the daycare memory unit of Centre Hospitalier Sud, Lyon, France. We searched the MEDLINE database (1973–2008) to identify drugs with anticholinergic properties. All drugs with well known anticholinergic activity, mild reported anticholinergic effects or in vitro anticholinergic activity were included in the study.

Measurements

We used the Free and Cued Selective Reminding (FCSR) test to evaluate verbal episodic memory.

Results

The mean±SD number of drugs with anticholinergic properties taken by the subjects was 0.64±0.82. Fifty percent of the subjects (n = 67) had a prescription for at least one drug with anticholinergic properties and 16% (n = 21) had a prescription for two or more. Drugs with anticholinergic properties most frequently prescribed in our cohort were cardiovascular (furosemide, hydrochlorothiazide, digoxin), antidepressant (paroxetine, sertraline, fluoxetine) and antispasmodic (oxybutynin chloride) drugs. The number of drugs with anticholinergic properties that subjects were taking was associated with reduced performance on tasks that assessed verbal memory (p < 0.05). Neuropsychological test batteries revealed a significant unfavourable effect of use of drugs with anticholinergic activity on episodic verbal memory. Tests evaluating other cognitive functions were not affected by use of drugs with anticholinergic activity. These associations remained following multivariate analysis adjusting for age, sex, education level, number of anticholinergic drugs, number of co-morbidities, diagnosis, behavioural symptoms and depressive symptoms.

Conclusion

Clinicians should assess the current use of drugs with anticholinergic properties in the elderly, particularly in patients presenting for memory evaluation. In such cases, use of other therapeutic alternatives should be considered.
Literatur
2.
Zurück zum Zitat Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol (Paris) 2003 Apr; 159(4): 405–11 Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol (Paris) 2003 Apr; 159(4): 405–11
3.
Zurück zum Zitat DeKosky ST. Neurobiology and molecular biology of Alzheimer’s disease. Rev Neurol 2002 Oct 16–31; 35(8): 752–60PubMed DeKosky ST. Neurobiology and molecular biology of Alzheimer’s disease. Rev Neurol 2002 Oct 16–31; 35(8): 752–60PubMed
4.
Zurück zum Zitat Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003 Feb; 60(2): 198–203PubMedCrossRef Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003 Feb; 60(2): 198–203PubMedCrossRef
5.
Zurück zum Zitat Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008 Mar 10; 168(5): 508–13PubMedCrossRef Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008 Mar 10; 168(5): 508–13PubMedCrossRef
6.
Zurück zum Zitat Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000 Apr; 5(2): 149–53PubMed Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000 Apr; 5(2): 149–53PubMed
7.
Zurück zum Zitat Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med 2005 Oct 10; 165(18): 2069–76PubMedCrossRef Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med 2005 Oct 10; 165(18): 2069–76PubMedCrossRef
8.
Zurück zum Zitat Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 2005 Feb; 59(2): 143–51PubMedCrossRef Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 2005 Feb; 59(2): 143–51PubMedCrossRef
9.
Zurück zum Zitat Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008 Mar; 83(3): 422–9PubMedCrossRef Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008 Mar; 83(3): 422–9PubMedCrossRef
10.
Zurück zum Zitat Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRef Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRef
11.
Zurück zum Zitat Cancelli I, Valentinis L, Merlino G, et al. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer’s disease. Clin Pharmacol Ther 2008 Jul; 84(1): 63–8PubMedCrossRef Cancelli I, Valentinis L, Merlino G, et al. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer’s disease. Clin Pharmacol Ther 2008 Jul; 84(1): 63–8PubMedCrossRef
12.
Zurück zum Zitat Uusvaara J, Pitkala KH, Tienari PJ, et al. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc 2009 Mar; 57(3): 427–31PubMedCrossRef Uusvaara J, Pitkala KH, Tienari PJ, et al. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc 2009 Mar; 57(3): 427–31PubMedCrossRef
13.
Zurück zum Zitat Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 Jul–Aug; 3(4): 335–48PubMedCrossRef Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 Jul–Aug; 3(4): 335–48PubMedCrossRef
14.
Zurück zum Zitat Rudd KM, Raehl CL, Bond CA, et al. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 2005 Nov; 25(11): 1592–601PubMedCrossRef Rudd KM, Raehl CL, Bond CA, et al. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 2005 Nov; 25(11): 1592–601PubMedCrossRef
15.
Zurück zum Zitat Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 Sep; 93(9): 457–62PubMed Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 Sep; 93(9): 457–62PubMed
16.
Zurück zum Zitat Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMed Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMed
17.
Zurück zum Zitat Thienhaus OJ, Allen A, Bennett JA, et al. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 1990; 240(1): 28–33PubMedCrossRef Thienhaus OJ, Allen A, Bennett JA, et al. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 1990; 240(1): 28–33PubMedCrossRef
19.
Zurück zum Zitat Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 Jan; 161(1): 116–24PubMedCrossRef Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 Jan; 161(1): 116–24PubMedCrossRef
20.
Zurück zum Zitat Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008 May 26; 56(7): 1333–41PubMedCrossRef Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008 May 26; 56(7): 1333–41PubMedCrossRef
21.
Zurück zum Zitat Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974 Jul; 31(1): 58–61PubMedCrossRef Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974 Jul; 31(1): 58–61PubMedCrossRef
22.
Zurück zum Zitat Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994 Nov; 69(11): 1069–81PubMedCrossRef Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994 Nov; 69(11): 1069–81PubMedCrossRef
23.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov; 12(3): 189–98PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov; 12(3): 189–98PubMedCrossRef
24.
Zurück zum Zitat Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004 Apr 27; 62(8): 1317–22PubMedCrossRef Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004 Apr 27; 62(8): 1317–22PubMedCrossRef
25.
Zurück zum Zitat Deloche GeH D. Test de dénomination orale d’images DO80. Paris: INSERM, 1997 Deloche GeH D. Test de dénomination orale d’images DO80. Paris: INSERM, 1997
26.
Zurück zum Zitat Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271–6 Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271–6
27.
Zurück zum Zitat Cardebat D, Doyon B, Puel M, et al. Formal and semantic lexical evocation in normal subjects: performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990; 90(4): 207–17PubMed Cardebat D, Doyon B, Puel M, et al. Formal and semantic lexical evocation in normal subjects: performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990; 90(4): 207–17PubMed
28.
Zurück zum Zitat Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988 Jun; 38(6): 900–3PubMedCrossRef Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988 Jun; 38(6): 900–3PubMedCrossRef
29.
Zurück zum Zitat Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987 May; 44(5): 418–26PubMedCrossRef Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987 May; 44(5): 418–26PubMedCrossRef
30.
Zurück zum Zitat Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008 Dec; 56(12): 2203–10PubMedCrossRef Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008 Dec; 56(12): 2203–10PubMedCrossRef
31.
Zurück zum Zitat Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009 Jul 27; 169(14): 1317–24PubMedCrossRef Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009 Jul 27; 169(14): 1317–24PubMedCrossRef
Metadaten
Titel
Effects of Anticholinergic Drugs on Verbal Episodic Memory Function in the Elderly
A Retrospective, Cross-Sectional Study
verfasst von
Dr Marie-Pierre Fortin
Isabelle Rouch
Virginie Dauphinot
Claire Gédéon
Stella Genthon
Marc Bonnefoy
Pierre Krolak-Salmon
Publikationsdatum
01.03.2011
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 3/2011
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/11586580-000000000-00000

Weitere Artikel der Ausgabe 3/2011

Drugs & Aging 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.